PET 68GA PSMA

Early detection of the diagnosis you are facing can significantly influence the clinical management of the disease.

Prostate cancer remains one of the leading causes of cancer-related deaths in men. Through this advanced revolutionary technique – 68Ga-PSMA, you can obtain precise information about the stage of your disease.

The PET investigation with a radiotracer [68Ga]-gallium-labelled Prostate-Specific Membrane Antigen (68Ga-PSMA) has proven to be highly successful in investigating and diagnosing prostate cancer, especially in detecting recurrences and metastases of prostate cancer. Moreover, molecular PET imaging with 68Ga-PSMA highlights suspicious lesions for prostate cancer with very good contrast and a very high detection rate, even when the prostate-specific antigen level is low.

This investigation is a vital element of today’s medical practice, adding an additional dimension to the early diagnosis of prostate cancer.